{"nctId":"NCT01208181","briefTitle":"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","startDateStruct":{"date":"2010-09-27","type":"ACTUAL"},"conditions":["Arthritis, Rheumatoid"],"count":1404,"armGroups":[{"label":"Etoricoxib 60 mg/Etoricoxib 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etoricoxib 60 mg","Drug: Placebo to Etoricoxib 60 mg"]},{"label":"Etoricoxib 60 mg/Etoricoxib 90 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etoricoxib 60 mg","Drug: Placebo to Etoricoxib 60 mg"]},{"label":"Etoricoxib 90 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etoricoxib 90 mg","Drug: Placebo to Etoricoxib 90 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to Etoricoxib 60 mg","Drug: Placebo to Etoricoxib 90 mg"]}],"interventions":[{"name":"Etoricoxib 60 mg","otherNames":["MK-0663"]},{"name":"Etoricoxib 90 mg","otherNames":["MK-0663"]},{"name":"Placebo to Etoricoxib 60 mg","otherNames":[]},{"name":"Placebo to Etoricoxib 90 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is male or female ≥ 18 years of age in general good health (other than RA)\n* Has an American College of Rheumatology Rheumatoid Clinical Response Criteria (ACR) Functional Class I, II, or III\n* Has a diagnosis of RA at least 6 months ago and was at least 16 years of age when diagnosed\n* Has a history of positive therapeutic benefit with nonsteroidal anti-inflammatory drugs (NSAIDs) and is taking an NSAID on a regular basis and at a therapeutic dose level and is not anticipated to undergo a change during the study\n\nExclusion Criteria:\n\n* Has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy\n* Has a history of gastric or biliary surgery (including gastric bypass surgery) or small intestine surgery that causes clinical malabsorption\n* Has an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease\n* Has a confirmed medical diagnosis of ischemic heart disease, cerebrovascular disease, or peripheral artery occlusive disease\n* Class II-IV congestive heart failure\n* Has uncontrolled hypertension (systolic \\>160 mm Hg or diastolic \\> 90 mm Hg) at Visit 1 or Visit 2\n* Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score ≥5\n* Has estimated glomerular filtration rate ≤30 mL/min\n* Has a history of neoplastic disease within 5 years (exceptions: basal cell carcinoma or carcinoma in situ of the cervix)\n* Is allergic to etoricoxib; history of a significant clinical or laboratory adverse experience associated with etoricoxib; hypersensitivity to aspirin or NSAIDs; or allergy to acetaminophen/paracetamol\n* Has a personal or family history of an inherited or acquired bleeding disorder\n* Requires oral corticosteroid therapy in excess of the equivalent of 10 mg daily of prednisone and/or have not been on a stable dose for at least 4 weeks prior to Visit 1 and/or whose dose is not expected to remain stable during the study\n* Treated with B-cell depleting therapies within the past 6 months or anticipate this treatment during this trial\n* Is a recreational or illicit drug use, or history within 5 years of drug or alcohol abuse/dependence;\n* Is morbidly obese (defined as body mass index ≥40 kg/m\\^2)\n* Is pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)","description":"Disease Activity Score Using C-Reactive Protein \\[DAS28-CRP\\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\\*square root (sqrt) (tender joint count \\[28\\])+0.28\\*sqrt(swollen joint count \\[28\\] )+0.36\\* ln(crp+1) + 0.014\\* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":null},{"groupId":"OG001","value":"-1.37","spread":null},{"groupId":"OG002","value":"-1.10","spread":null}]}]}]},{"type":"PRIMARY","title":"Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)","description":"A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker \"no pain\" (0 mm) or right-hand marker \"extreme pain\" (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.25","spread":null},{"groupId":"OG001","value":"-30.96","spread":null},{"groupId":"OG002","value":"-20.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)","description":"Disease Activity Score Using C-Reactive Protein \\[DAS28-CRP\\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\\*square root (sqrt) (tender joint count \\[28\\])+0.28\\*sqrt(swollen joint count \\[28\\] )+0.36\\* ln(crp+1) + 0.014\\* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":null},{"groupId":"OG001","value":"-1.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)","description":"A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker \"no pain\" (0 mm) or right-hand marker \"extreme pain\" (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.25","spread":null},{"groupId":"OG001","value":"-30.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1","description":"A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker \"no pain\" (0 mm) or right-hand marker \"extreme pain\" (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with \\<50% improvement from baseline in PGAP \\[VAS\\] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.96","spread":null},{"groupId":"OG001","value":"-10.35","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event (AE)","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"19.1","spread":null},{"groupId":"OG003","value":"24.5","spread":null},{"groupId":"OG004","value":"25.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Study Drug Due to an AE","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"1.4","spread":null},{"groupId":"OG003","value":"1.9","spread":null},{"groupId":"OG004","value":"3.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":819},"commonTop":["Headache"]}}}